Recent global partnership initiatives have focused on stimulating further interest in the development and provision of drugs for the world's top three killer infectious diseases: AIDS/HIV, malaria, and tuberculosis. The "most neglected" diseases (where there are no affordable, effective, easy to use medicines available) continue to cause significant morbidity and mortality in developing countries.
A series of articles in this journal (The Lancet) will outline research and development priorities for three neglected diseases prevalent in the developing world: human African trypanosomiasis (sleeping sickness) in this issue , visceral leishmaniasis (kala azar) in August, and malaria in September.
Only 10% of expenditure on health research is on those diseases that account for 90% of the global burden of disease.
Why did a public private partnership so successful in developing treatment for river blindness? Because of high-profile advocacy in the west - including efforts by former US President Jimmy Carter's "Carter Foundation",